News
Kynos Therapeutics targets inflammation-driven illness
Kynos Therapeutics has announced major financing to support its lead KMO inhibitor (KMOi) programme through phase 1 clinical trials. It will also progress its innovative pipeline of first-in-class KMOi across key indications in inflammation, immunity and metabolism.